TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21489291

Group type: COMPARATOR
Intervention: 0 Gy radiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 Gy radiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 Gy radiation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 Gy radiation
Number of subjects: 40
Study: 18389243

Group type: EXPERIMENTAL
Intervention: MR imaging of the proximal femur measuring red marrow area percentage
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Red marrow area percentage
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Marrow hemosiderosis and duration of symptoms and serum ferritin
Number of subjects: 27
Study: 17219490

Group type: EXPERIMENTAL
Intervention: Scripted intervention providing detailed information about CPR, MV, and advance directives
Number of subjects: 297

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Scripted intervention
Number of subjects: 297
Study: 12505859

Group type: EXPERIMENTAL
Intervention: 12-month maintenance intervention with weekly telephone contacts and monthly supervised reinforcement sessions (n = 87)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard care (n = 85)
Number of subjects: 172
Study: 10868721

Group type: EXPERIMENTAL
Intervention: Frontal Lobe Score (FLS)
Number of subjects: 118
Study: 9049568

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg zinc as sulphate)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A (800 micrograms retinol palmitate)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg zinc as sulphate)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (starch containing capsules)
Number of subjects: 118
Study: 8478172

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iopentol (contrast medium)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iodixanol (contrast medium)
Number of subjects: 30
Study: 3530768

Group type: EXPERIMENTAL
Intervention: Amrinone withdrawal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (during the first or second 6 week period)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Open withholding of amrinone for another 6 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amrinone (in 2 patients)
Number of subjects: 14
Study: 30057052

Group type: EXPERIMENTAL
Intervention: Ice massage (40 min)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ice massage (80 min)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no ice massage)
Number of subjects: 72
Study: 27594122

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 1720
Study: 24968124

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoint KI3
Number of subjects: 24
Study: 22686358

Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy (CBT) for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 47
Study: 19860985

Group type: EXPERIMENTAL
Intervention: 500 mg Ca as calcium carbonate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Absence of Ca
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Presence of Ca
Number of subjects: 13
Study: 17915969

Group type: EXPERIMENTAL
Intervention: Topiramate (target daily dose, 200 mg) plus cognitive-behavior therapy (CBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo plus cognitive-behavior therapy (CBT)
Number of subjects: 73
Study: 15618102

Group type: EXPERIMENTAL
Intervention: Web-based (WB) modules
Number of subjects: 75

Group type: COMPARATOR
Intervention: Paper practice guidelines
Number of subjects: 75
Study: 12153602

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CPA 2 mg with 35 micro g ethinylestradiol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CPA 50 mg with 25 micro g ethinylestradiol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 48
Study: 10434235

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (oral single dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (normolipemic subjects)
Number of subjects: 48
Study: 7607582

Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal LDL precipitation (HELP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no HELP treatment)
Number of subjects: 30
Study: 2198908

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 29600401

Group type: EXPERIMENTAL
Intervention: Early voiding trial (4 hours post-operatively on the day of surgery)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard voiding trial (6 am on post-operative day 1)
Number of subjects: 57
Study: 30151821

Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 300
Study: 26254585

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 10 μg/kg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Atropine 15 μg/kg
Number of subjects: 74
Study: 23157466

Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 10 mg twice daily
Number of subjects: 0
Study: 21545485

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg with fluconazole 200 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fesoterodine 8 mg alone
Number of subjects: 28
Study: 19932842

Group type: EXPERIMENTAL
Intervention: Monopolar cautery tonsillectomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 114
Study: 16492851

Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block (ICB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Humeral block (HB)
Number of subjects: 104
Study: 15534127

Group type: EXPERIMENTAL
Intervention: ROP-randomized group
Number of subjects: 244

Group type: COMPARATOR
Intervention: No-ROP group
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: ROP-randomized children
Number of subjects: 244

Group type: COMPARATOR
Intervention: No-ROP children
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Sighted-randomized children
Number of subjects: 244

Group type: COMPARATOR
Intervention: Blind/low vision children
Number of subjects: 244
Study: 11006189

Group type: EXPERIMENTAL
Intervention: 200 mg lignocaine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 150 mg lignocaine
Number of subjects: 150
Study: 9037324

Group type: EXPERIMENTAL
Intervention: Dippers (group 1) - 46 subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nondippers (group 2) - 54 subjects
Number of subjects: 100
Study: 8315702

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3565792

Group type: EXPERIMENTAL
Intervention: Halothane (0.5%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enflurane (0.8%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Meperidine (group III)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Halothane (0.5%) and Enflurane (0.8%)
Number of subjects: 24
Study: 28890326

Group type: EXPERIMENTAL
Intervention: TauroLock™‐Hep500 used twice per week and TauroLock™‐U25,000 once a week
Number of subjects: 106
Study: 27890482

Group type: EXPERIMENTAL
Intervention: Beetroot juice (a rich source of NO3‐) for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 20
Study: 24297945

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously, weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Interferon alfa (9 MIU subcutaneously thrice weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Temsirolimus/bevacizumab
Number of subjects: 791

Group type: COMPARATOR
Intervention: Interferon alfa/bevacizumab
Number of subjects: 791
Study: 22569889

Group type: EXPERIMENTAL
Intervention: Measured cuff BP in current clinical practice
Number of subjects: 225

Group type: COMPARATOR
Intervention: Assuming perfect sphygmomanometer measurement
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Casual clinical visit based on JNC 7 guideline
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Time of clinic visit
Number of subjects: 225
Study: 20975026

Group type: EXPERIMENTAL
Intervention: Intervention group (physicians in intervention practices)
Number of subjects: 2847

Group type: COMPARATOR
Intervention: Control group (physicians in control practices)
Number of subjects: 2847
Study: 18799426

Group type: EXPERIMENTAL
Intervention: 50 mg of naltrexone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16517306

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle reconstruction (group AD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single-bundle reconstruction (group S)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonanatomic double-bundle reconstruction (group N-AD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study: 12543884

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty (plus medication if necessary)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 210
Study: 11696071

Group type: EXPERIMENTAL
Intervention: 1.8 mg sustained-release melatonin 0.5 h before daytime sleep episodes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo before daytime sleep episodes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.8 mg sustained-release melatonin
Number of subjects: 21
Study: 9715537

Group type: EXPERIMENTAL
Intervention: Electrophoresis of serum for 'M' band and Immunoelectrophoretic analysis of the serum
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Detection of urinary Bence Jones proteins
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Kappa and lambda light chain analysis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sequential follow-up study
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Triangular approach to diagnosis of paraproteinemia
Number of subjects: 72
Study: 12959304

Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine (6-MP)
Number of subjects: 149
Study: 3107483

Group type: EXPERIMENTAL
Intervention: Non-steroidal antirheumatic drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enthesis index (EI)
Number of subjects: 0
Study: 31760817

Group type: EXPERIMENTAL
Intervention: Letter plus reminder call (RC)
Number of subjects: 3215

Group type: EXPERIMENTAL
Intervention: Two letters plus educational material and a counseling call (CC)
Number of subjects: 3215

Group type: COMPARATOR
Intervention: Reminder letter only (LO)
Number of subjects: 3215

Group type: EXPERIMENTAL
Intervention: CC
Number of subjects: 3215

Group type: EXPERIMENTAL
Intervention: RC
Number of subjects: 3215
Study: 30714310

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 28127948

Group type: EXPERIMENTAL
Intervention: Reformulated DTC capsule (Duodart®) 0.5 mg dutasteride and 0.4 mg tamsulosin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Commercial formulation of dutasteride and tamsulosin
Number of subjects: 2
Study: 26560823

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine (CHX) varnish
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo varnish (control)
Number of subjects: 30
Study: 23739024

Group type: EXPERIMENTAL
Intervention: Early intervention practices
Number of subjects: 26005

Group type: COMPARATOR
Intervention: Delayed intervention practices
Number of subjects: 26005

Group type: EXPERIMENTAL
Intervention: Medication for alcohol use disorders
Number of subjects: 26005
Study: 19846269

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg i.v.) or Prednisone (40 mg by mouth × 2 days)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 19267711

Group type: COMPARATOR
Intervention: Pio + ADA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pio + PC
Number of subjects: 51

Group type: COMPARATOR
Intervention: Met + ADA
Number of subjects: 51
Study: 16614786

Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Parent training combined with child therapy (CT)
Number of subjects: 127
Study: 15378678

Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg; oral)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg, s.c.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg) + scopolamine (0.4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 11520711

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice a day
Number of subjects: 232

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice a day (in Australasian population)
Number of subjects: 232

Group type: COMPARATOR
Intervention: placebo (in Australasian population)
Number of subjects: 232
Study: 9039862

Group type: EXPERIMENTAL
Intervention: Indoor fungus concentrations in asthmatic children
Number of subjects: 92

Group type: COMPARATOR
Intervention: Indoor fungus concentrations in control children
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Total fungus concentrations
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cladosporium and Penicillium concentrations
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Aspergillus, Cladosporium, Penicillium, and yeast concentrations
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Home dampness
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cladosporium occurrence
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Penicillium concentrations
Number of subjects: 92
Study: 7950836

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 84
Study: 2969910

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 6
Study: 29034443

Group type: EXPERIMENTAL
Intervention: Intraligamentary anesthesia (ILA)
Number of subjects: 266
Study: 27474888

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0
Study: 24796049

Group type: EXPERIMENTAL
Intervention: Palpation at the running course of 12 regular meridians and back-shu points in bronchial asthma patients
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Palpation at back-shu points
Number of subjects: 96
Study: 22585212

Group type: EXPERIMENTAL
Intervention: Miltefosine dosing algorithm based on allometric scaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allometric dosing algorithm for miltefosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New allometric dosing algorithm for miltefosine
Number of subjects: 0
Study: 21092030

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (Group NP)
Number of subjects: 289
Study: 17885789

Group type: EXPERIMENTAL
Intervention: Mesh fixation by metal tacks
Number of subjects: 360

Group type: COMPARATOR
Intervention: Unfixated mesh
Number of subjects: 360
Study: 15942317

Group type: EXPERIMENTAL
Intervention: OASIS Wound Matrix
Number of subjects: 73

Group type: COMPARATOR
Intervention: Regranex Gel
Number of subjects: 73
Study: 12843202

Group type: EXPERIMENTAL
Intervention: Ghrelin (1 micro g/Kg iv)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GHRH (1 micro g/Kg iv)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GHRH plus Ghrelin (1 micro g/Kg iv)
Number of subjects: 2
Study: 10472341

Group type: EXPERIMENTAL
Intervention: GnRH analog triptorelin (3.75 mg i.m. monthly)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of triptorelin and aromatase inhibitor formestane (4‐OHA, 500 mg i.m. fortnightly)
Number of subjects: 21
Study: 8933496

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g creatine monohydrate 4 times per day for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (same dosage of a lactose placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1655227

Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2) and Doxorubicin (70 mg/m2) every 3 weeks for four cycles
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1000 mg/m2 every 21 days for six cycles)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Whole-abdominal radiation therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (refusal of SLL)
Number of subjects: 61
Study: 7058508

Group type: EXPERIMENTAL
Intervention: Caffeine-free diet (abstaining from methylxanthine-containing foods and beverages)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No dietary recommendations (controls)
Number of subjects: 158
Study: 30996057

Group type: EXPERIMENTAL
Intervention: High-frequency transcranial magnetic stimulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-intensity sham stimulation
Number of subjects: 15
Study: 30309787

Group type: EXPERIMENTAL
Intervention: HITSystem
Number of subjects: 690

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: HITSystem (modified intention-to-treat)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Standard of care (modified intention-to-treat)
Number of subjects: 690
Study: 26624976

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 800 μg (total dose 800 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 400 μg (total dose 400 μg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluticasone Propionate Diskus 400 μg (total dose 400 μg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 800 μg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI 400 μg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluticasone Propionate Diskus 400 μg
Number of subjects: 30
Study: 24935879

Group type: EXPERIMENTAL
Intervention: High-valence condition (n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-valence condition (n = 8)
Number of subjects: 15
Study: 22548646

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg, 100 mg, 200 mg, 300 mg daily, or 300 mg twice daily
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control (placebo/sitagliptin)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control
Number of subjects: 289
Study: 20623038

Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 17390738

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Q2W)
Number of subjects: 1101
Study: 15818684

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 12683736

Group type: EXPERIMENTAL
Intervention: Intervention group received a message from their physician, a self-help manual, written personalized feedback, and up to 3 telephone counseling calls.
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 307
Study: 10353069

Group type: EXPERIMENTAL
Intervention: Military fighter pilots (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Military ground personnel (group A)
Number of subjects: 100
Study: 7795772

Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal lactation instruction from a lactation consultant
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard of care (no lactation consultant)
Number of subjects: 108
Study: 1819435

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose Schwarz vaccine at 4-5 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose Edmonston-Zagreb vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Schwarz vaccine for seropositive children
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AIK-C vaccine at 8-10 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Schwarz vaccine at 8-10 months
Number of subjects: 5

Group type: COMPARATOR
Intervention: High-dose Edmonston-Zagreb or AIK-C at 4-5 months
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard dose Schwarz at 8-10 months
Number of subjects: 5
Study: 7274609

Group type: EXPERIMENTAL
Intervention: CaCl2 (60 mmole orally over 24 h for 3 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MgCl2 (60 mmole orally over 24 h for 3 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MgCl2 (60 mmole daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mg(OH)2 (60 mmole daily)
Number of subjects: 11
Study: 30520566

Group type: EXPERIMENTAL
Intervention: Pegbelfermin 20 mg daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pegbelfermin (1, 5, or 20 mg daily or 20 mg weekly)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pegbelfermin 20 mg daily and weekly
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120